Kindlin-2 haploinsufficiency protects against fatty liver by targeting Foxo1 in mice

[1]  Huiling Cao,et al.  Pinch Loss Ameliorates Obesity, Glucose Intolerance, and Fatty Liver by Modulating Adipocyte Apoptosis in Mice , 2021, Diabetes.

[2]  V. Rangnekar,et al.  Lessons from Mouse Models , 2021, Tumor Suppressor Par-4.

[3]  Huiling Cao,et al.  Kindlin-2 regulates skeletal homeostasis by modulating PTH1R in mice , 2020, Signal Transduction and Targeted Therapy.

[4]  Hu Zhou,et al.  S100A11 Promotes Liver Steatosis via FOXO1-Mediated Autophagy and Lipogenesis , 2020, Cellular and molecular gastroenterology and hepatology.

[5]  A. Suzuki,et al.  Tackling NAFLD: Three Targeted Populations. , 2020, Hepatology.

[6]  Zeyu Cai,et al.  Kindlin-2 deficiency induces fatal intestinal obstruction in mice , 2020, Theranostics.

[7]  J. Dufour,et al.  Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges , 2020, Gut.

[8]  Haozhen Ren,et al.  Protective Properties of FOXO1 Inhibition in a Murine Model of Non-alcoholic Fatty Liver Disease Are Associated With Attenuation of ER Stress and Necroptosis , 2020, Frontiers in Physiology.

[9]  K. Clément,et al.  Nonalcoholic fatty liver disease: modulating gut microbiota to improve severity? , 2020, Gastroenterology.

[10]  Di Chen,et al.  Focal adhesion protein Kindlin-2 regulates bone homeostasis in mice , 2020, Bone Research.

[11]  C. Byrne,et al.  What’s new in NAFLD pathogenesis, biomarkers and treatment? , 2019, Nature Reviews Gastroenterology & Hepatology.

[12]  W. Kong,et al.  Kindlin-2 suppresses transcription factor GATA4 through interaction with SUV39H1 to attenuate hypertrophy , 2019, Cell Death & Disease.

[13]  E. Albano,et al.  Adaptive immunity: an emerging player in the progression of NAFLD , 2019, Nature Reviews Gastroenterology & Hepatology.

[14]  A. Cárdenas,et al.  Endoscopic bariatric and metabolic therapies for non-alcoholic fatty liver disease. , 2019, Journal of hepatology.

[15]  Wei Yang,et al.  Lipoatrophy and metabolic disturbance in mice with adipose-specific deletion of kindlin-2. , 2019, JCI insight.

[16]  K. Cusi,et al.  Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. , 2019, The lancet. Diabetes & endocrinology.

[17]  Ju Chen,et al.  Kindlin-2 Is Essential for Preserving Integrity of the Developing Heart and Preventing Ventricular Rupture. , 2019, Circulation.

[18]  Z. Younossi.  Non-alcoholic fatty liver disease - A global public health perspective. , 2019, Journal of hepatology.

[19]  Ji-Young Kim,et al.  FOXO1 degradation via G9a-mediated methylation promotes cell proliferation in colon cancer , 2018, Nucleic acids research.

[20]  Qinghai Li,et al.  Kindlin-2 regulates hepatic stellate cells activation and liver fibrogenesis , 2018, Cell Death Discovery.

[21]  E. Harris,et al.  Purification of Hepatocytes and Sinusoidal Endothelial Cells from Mouse Liver Perfusion , 2018, Journal of visualized experiments : JoVE.

[22]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[23]  Ying Sun,et al.  Kindlin-2 Association with Rho GDP-Dissociation Inhibitor α Suppresses Rac1 Activation and Podocyte Injury. , 2017, Journal of the American Society of Nephrology : JASN.

[24]  Wansong Lin,et al.  Kindlin-2 promotes hepatocellular carcinoma invasion and metastasis by increasing Wnt/β-catenin signaling , 2017, Journal of experimental & clinical cancer research : CR.

[25]  X. Ruan,et al.  Suppression of CD36 attenuates adipogenesis with a reduction of P2X7 expression in 3T3-L1 cells. , 2017, Biochemical and biophysical research communications.

[26]  Hongli Jiao,et al.  Kindlin-2 controls TGF-β signalling and Sox9 expression to regulate chondrogenesis , 2015, Nature Communications.

[27]  C. Byrne,et al.  NAFLD: a multisystem disease. , 2015, Journal of hepatology.

[28]  G. Targher,et al.  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis , 2013, Nature Reviews Gastroenterology &Hepatology.

[29]  Yuhao Li,et al.  Treatment with Ginger Ameliorates Fructose-Induced Fatty Liver and Hypertriglyceridemia in Rats: Modulation of the Hepatic Carbohydrate Response Element-Binding Protein-Mediated Pathway , 2012, Evidence-based complementary and alternative medicine : eCAM.

[30]  H. Mustonen,et al.  Kindlin-2: a novel adhesion protein related to tumor invasion, lymph node metastasis, and patient outcome in gastric cancer. , 2012, American journal of surgery.

[31]  Jichun Yang,et al.  Pancreatic‐derived factor promotes lipogenesis in the mouse liver: Role of the Forkhead box 1 signaling pathway , 2011, Hepatology.

[32]  M. White,et al.  Regulation of glucose homeostasis through a XBP-1–FoxO1 interaction , 2011, Nature Medicine.

[33]  Zhiyong Cheng,et al.  Targeting Forkhead box O1 from the concept to metabolic diseases: lessons from mouse models. , 2011, Antioxidants & redox signaling.

[34]  R. Fässler,et al.  The Tail of Integrins, Talin, and Kindlins , 2009, Science.

[35]  H. Larjava,et al.  Kindlins: essential regulators of integrin signalling and cell–matrix adhesion , 2008, EMBO reports.

[36]  J. Golden,et al.  Kindlin-2 is required for myocyte elongation and is essential for myogenesis , 2008 .

[37]  L. N. Valenti,et al.  Increased Expression and Activity of the Transcription Factor FOXO1 in Nonalcoholic Steatohepatitis , 2007, Diabetes.

[38]  R. DePinho,et al.  Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. , 2007, Cell metabolism.

[39]  D. Accili,et al.  Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. , 2006, The Journal of clinical investigation.

[40]  T. Unterman,et al.  FoxO proteins in insulin action and metabolism , 2005, Trends in Endocrinology & Metabolism.

[41]  D. Tindall,et al.  Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Hitomi Matsuzaki,et al.  Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[43]  G. Jacquemin.  [Nonalcoholic steatohepatitis: a review]. , 2003, Revue medicale de Liege.

[44]  Jerry Donovan,et al.  Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. , 2003, Nature.

[45]  Robert C. Wolpert,et al.  A Review of the , 1985 .